Coverage
-
February 28, 2023
Buyers of a generic epilepsy drug aren't so numerous that they must be allowed to band together in a class action rather than joining their suits together traditionally, said a New Jersey federal judge who has refused to certify their class in an antitrust suit against drugmakers GlaxoSmithKline and Teva Pharmaceuticals.
19 other articles on this case.
View all »